

# **C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/CA1A10E1261DEN.html>

Date: September 2022

Pages: 89

Price: US\$ 3,500.00 (Single User License)

ID: CA1A10E1261DEN

## **Abstracts**

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

According to the recently published report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022'; C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.

The report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022' outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis

by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Central Nervous System, Oncology, Respiratory, Gastrointestinal and Toxicology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Coronavirus Disease 2019 (COVID-19), Multiple Sclerosis, Chronic Obstructive Pulmonary Disease (COPD), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19) Pneumonia, Diabetic Neuropathic Pain, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Opioid Induced Side Effects, Opium (Opioid) Addiction, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Post-Acute Sequelae of COVID 2019 (PASC or Long COVID), Post-Operative Pain, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on

information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development

American Gene Technologies International Inc

Aphios Corp

Bristol-Myers Squibb Co

Creative Bio-Peptides Inc

Cytodyn Inc

Forest Hills Partners Hong Kong Ltd

GSK plc

Merck & Co Inc

Novartis AG

Orion Biotechnology Canada Ltd

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles

(cenicriviroc + tropifexor) - Drug Profile

Product Description

Mechanism Of Action

History of Events

AG-1105 - Drug Profile

Product Description

Mechanism Of Action

History of Events

APH-1701 - Drug Profile

Product Description

Mechanism Of Action

BMS-813160 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile

Product Description

Mechanism Of Action

DS-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DS-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DS-005 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Ieronlimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

maraviroc - Drug Profile

Product Description

Mechanism Of Action

History of Events

maraviroc - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile

Product Description

Mechanism Of Action

History of Events

OB-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

OB-002M - Drug Profile

Product Description

Mechanism Of Action

History of Events

RAP-103 - Drug Profile

Product Description

Mechanism Of Action

History of Events

vicriviroc - Drug Profile

Product Description

Mechanism Of Action

History of Events

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones

Featured News & Press Releases

Jul 28, 2022: American Gene Technologies' HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals

Jul 19, 2022: Preclinical Data Demonstrate Potential of Creative Bio-Peptides' Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression

Jul 14, 2022: Preclinical data demonstrate potential of Creative Bio-Peptides' multi-chemokine receptor antagonist RAP-103 to provide opioid sparing post-surgical pain relief and treatment for chronic pain

Jul 11, 2022: CytoDyn highlights NIH Grant for HIV functional cure preclinical study of gene therapy based on leronlimab

Apr 12, 2022: CytoDyn announces publication of peer-reviewed paper, "Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody leronlimab in two species"

Mar 31, 2022: FDA places full clinical hold on CytoDyn's Covid-19 programme

Feb 24, 2022: American Gene Technologies advances closer to demonstrating a

potential cure for HIV

Feb 02, 2022: American Gene Technologies' HIV clinical trial shows blood markers of efficacy in two more patients

Jan 25, 2022: CytoDyn announces leadership transition plan to support regulatory approval and commercialization of Leronlimab

Jan 13, 2022: CytoDyn cancels webcast and live Q/A scheduled for today

Jan 10, 2022: Published paper indicates leronlimab shows activity against 4-class drug resistant HIV-1 from heavily treatment experienced ("HTE") subjects

Jan 05, 2022: Leronlimab 14-week, NASH clinical trial met primary endpoint (PDFF) and secondary endpoint (cT1) for per protocol population in 350 mg weekly dose

Dec 22, 2021: FDA provides positive response to begin CytoDyn's Covid-19 antibody trial

Dec 21, 2021: American Gene Technologies' HIV clinical trial demonstrates blood markers of efficacy

Dec 13, 2021: NASH phase 2 trial open-label portion demonstrates average 80 msec cT1 reduction in 50% of patients and reduction of nearly 50 msec in 80% of patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indications, 2022  
Number of Products under Development by Indications, 2022 (Contd..1)  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pipeline by American Gene Technologies International Inc, 2022  
Pipeline by Aphios Corp, 2022  
Pipeline by Bristol-Myers Squibb Co, 2022  
Pipeline by Creative Bio-Peptides Inc, 2022  
Pipeline by Cytodyn Inc, 2022  
Pipeline by Forest Hills Partners Hong Kong Ltd, 2022  
Pipeline by GSK plc, 2022  
Pipeline by Merck & Co Inc, 2022  
Pipeline by Novartis AG, 2022  
Pipeline by Orion Biotechnology Canada Ltd, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Dormant Products, 2022 (Contd..2)  
Dormant Products, 2022 (Contd..3)  
Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CA1A10E1261DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA1A10E1261DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970